{"id":404192,"date":"2020-12-22T01:33:20","date_gmt":"2020-12-22T06:33:20","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=404192"},"modified":"2020-12-22T01:33:20","modified_gmt":"2020-12-22T06:33:20","slug":"nicoxs-licensee-bausch-lomb-secures-approval-of-vyzulta-in-colombia","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nicoxs-licensee-bausch-lomb-secures-approval-of-vyzulta-in-colombia\/","title":{"rendered":"Nicox\u2019s Licensee Bausch + Lomb Secures Approval of VYZULTA in Colombia"},"content":{"rendered":"
\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n Press Release<\/strong>\n <\/td>\n<\/tr>\n
Nicox\u2019s Licensee Bausch + Lomb Secures Approval of VYZULTA\u00ae<\/sup> in Colombia<\/td>\n<\/tr>\n
\n \u00a0<\/strong><\/p>\n

December 22, 2020 \u2013 release at 7:30 am CET
Sophia Antipolis, France\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/p>\n

\u00a0<\/p>\n

Nicox SA<\/strong> (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that its partner, Bausch + Lomb, has received approval for latanoprostene bunod ophthalmic solution, 0.024% (marketed as VYZULTA\u00ae<\/sup> In the United States) in Colombia, where it will be marketed under the brand name CLIROPTA\u00ae<\/sup>.<\/p>\n

VYZULTA is currently commercialized in the United States, Canada and Argentina and approved in 5 other territories \u2013 Colombia, Hong Kong, Mexico, Taiwan and Ukraine – for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. \u00a0Bausch + Lomb will continue seeking approvals in territories where the clinical data package, part of the U.S. New Drug Application, can be used for approval by the regulatory authorities. <\/p>\n

\u00a0<\/p>\n

Under the terms of the exclusive license agreement with Bausch + Lomb, Nicox receives increasing tiered
royalties of 6% to 12% on net global sales of VYZULTA plus up to $150 million in potential future milestones
payments.<\/p>\n

\u00a0<\/p>\n

Bausch + Lomb is a leading global eye health business of Bausch Health Companies Inc. (NYSE\/TSX:
BHC).<\/td>\n<\/tr>\n

\n \u00a0<\/strong><\/p>\n

About Nicox<\/strong>\n <\/td>\n<\/tr>\n

Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health.\u00a0 Nicox\u2019s lead program in clinical development is NCX 470, a novel, second-generation nitric oxide-donating bimatoprost analog, for lowering intraocular pressure in patients with glaucoma.\u00a0 The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis.\u00a0 Nicox generates revenue from VYZULTA\u00ae<\/sup> in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE\u2122 in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of South East Asian markets.\u00a0 <\/p>\n

Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. <\/p>\n

For more information on Nicox, its products or pipeline, please visit: www.nicox.com<\/u><\/a>.<\/u><\/td>\n<\/tr>\n

\n Analyst coverage<\/strong>\n <\/td>\n<\/tr>\n
\u00a0<\/p>\n

Bryan, Garnier & Co \u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0Victor Floc\u2019h\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Paris, France
Cantor Fitzgerald\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0 Louise Chen\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 New York, U.S.
H.C. Wainwright & Co \u00a0\u00a0\u00a0\u00a0 Yi Chen\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 New York, U.S.
Kepler Cheuvreux\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0 Damien Choplain\u00a0\u00a0 Paris, France
Oppenheimer & Co\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0 Hartaj Singh\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 New York, U.S.<\/td>\n

\u00a0<\/td>\n<\/tr>\n
\n The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. \u00a0Nicox disavows any obligation to correct or to update the information contained in analyst reports.<\/em><\/p>\n

\u00a0<\/em>\n <\/td>\n<\/tr>\n

\n Contacts<\/strong>\n <\/td>\n<\/tr>\n
\n Nicox<\/strong>
\n
Gavin Spencer
Executive Vice President, Chief Business Officer
& Head of Corporate Development\u00a0
T +33 (0)4 97 24 53 00
communications@nicox.com <\/u><\/a><\/td>\n<\/tr>\n
Investors & Media
United States & Europe
LifeSci Advisors, LLC
Mary-Ann Chang
T +44 7483 284 853
mchang@lifesciadvisors.com<\/u><\/a><\/td>\n		Media
France
LifeSci Advisors, LLC
Sophie Baumont
M +33 (0)6 27 74 74 49
sophie@lifesciadvisors.com<\/u><\/a><\/td>\n<\/tr>\n
\n Forward-Looking Statements<\/strong>\n <\/td>\n<\/tr>\n
The information contained in this document may be modified without prior notice. \u00a0This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. \u00a0These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. \u00a0Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.<\/p>\n

Risks factors which are likely to have a material effect on Nicox\u2019s business are presented in the 3rd<\/sup> chapter of the \u2018Document d\u2019enregistrement universel, rapport financier annuel et rapport de gestion 2019<\/em>\u2019 filed with the French Autorit\u00e9 des March\u00e9s Financiers<\/em> (AMF) on March 6, 2020 which is available on Nicox\u2019s website (www.nicox.com<\/u><\/a>) and in the 4th<\/sup> chapter of the half yearly financial report as of June 30, 2020, which is also available on Nicox\u2019s website..<\/td>\n<\/tr>\n

\n Nicox S.A.<\/strong>
\n
Drakkar 2
B\u00e2t D, 2405 route des Dolines
CS 10313, Sophia Antipolis
06560 Valbonne, France
T +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99<\/td>\n<\/tr>\n<\/table>\n

\u00a0<\/p>\n

\n Attachment<\/strong>\n <\/p>\n